The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …

Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …

Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …